Early Warning System

EIB-20240783 MAAT PHARMA (IEU-LS)



Early Warning System MAAT PHARMA (IEU-LS)

Quick Facts

Countries	France
Specific Location	Lyon
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2025-07-25
Borrower	MaaT Pharma
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 44.64 million
Project Cost (USD)	\$ 103.37 million

Project Description

According to the Bank's website, the project supports the promoter's research, development and innovation (RDI) investments to develop microbiome-based therapies that aim to treat serious diseases by restoring the microbiome balance, including immune-related conditions and cancer.

The aim is to support the promoter's RDI investments, including proprietary clinical-stage assets, continued platform development, and the activities required to enable manufacturing scale-up.

The EIB financing will also support the steps leading up to the market launch of the most advanced products.

The project will be coordinated from MaaT Pharma's headquarters in Lyon.

Investment Description

• European Investment Bank (EIB)

Private Actors Description

MaaT Pharma is a clinical-stage oncology company that develops microbiome restoration therapies. The Company is headquartered in Lyon.



Early Warning System MAAT PHARMA (IEU-LS)

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	MaaT Pharma	Client	-

Contact Information

No contacts available at the time of disclosure.

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check:

http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces